TSE advisory committee
This article was originally published in The Gray Sheet
Executive Summary
Upcoming Feb. 20 Transmissible Spongiform Encephalopathies advisory committee meeting will address implementation of the final guidance on preventive measures to reduce the possible risk of transmission of CJD and vCJD disease by blood and blood products and the document's ramifications on the blood supply. The guidance was issued in January 2002. Also on the agenda is a discussion of labeling claims for TSE agent clearance in plasma derivatives...
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.